 2009 iMedia neuroScoop.net / anocef.org Chimiothérapie Khê Hoang-Xuan Paris.

Slides:

Advertisements

Similar presentations

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Advertisements

Palumbo A et al. Proc ASH 2013;Abstract 536.

Phase IB Trial of Carboxyamidotriazole Orotate (CTO) and Temozolomide for Recurrent Malignant Glioma (MG): A Novel Mechanism for Modulation of Multiple.

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting

47 year-old female patient Headheachs since 3 months Tired Too heavy word, end of the year…? Late July 2008 Consultations Family doctor Neurologist.

Chemotherapy and trials for brain tumours

Medical Treatment for High Grade Gliomas – An Overview

Academic & Community Cancer Research United (ACCRU) Scientific Achievements.

B Y : J AHNAVI U DAIKUMAR D IRECTOR : D R. R ICHARD S ANKER, P H D R ETROSPECTIVE A NALYSIS ON D IFFERENTIAL E FFECTS OF T REATMENT S TRATEGY ON O UTCOME.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.

ANDY LIM Surgical HMO2.  Classification  Clinical presentation  Investigations  Management.

Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma A. Thomas.

Copyright © 2010, Research To Practice, All rights reserved. Part V: Central Nervous System Cancers Monday, October 18, :30 PM - 8:30 PM ET Monday.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.

QUANTITATIVE MRI OF GLIOBLASTOMA RESPONSE Bruce Rosen, MD, PhD Athinoula A. Martinos Center for Biomedical Imaging, MGH. Future Plans/Upcoming Trials Reproducibility.

Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”

Discussion abstracts Alberto Sobrero MD Ospedale San Martino Genoa, Italy.

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

Methods Patients: Unresectable GBM PS 0-2, MMS≥25 Centralized radiological Review RANO criteria Centralized pathological Review: MGMT tissue & MGMT serum.

HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.

Shin-Ichi Miyatake, MD., Ph.D. Shinji Kawabata, Motomasa Furuse, Gen Futamura, et al. Dept. of Neurosurgery, Cancer Center Osaka Medical College 16 th.

Irradiation of stem cell niches in the periventricular and sub granular zones in gbm : A Prospective study Akram K S, Monica I, Deepa J, Kesava R, Fayaz.

FDA Oncologic Drugs Advisory Committee Pediatric Oncology Subcommittee Endpoints for New Drugs to Treat Pediatric Brain Tumors 6 December 2006.

Randomized Phase II Study of Whole-Brain Radiation Therapy with or without Concomitant Temozolomide for Brain Metastases from Breast Cancer K. I. CAO 1,

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

WHAT WILL THE KEY ISSUES IN END- POINT ASSESSMENT BE, IN FUTURE OVARIAN CANCER TRIALS INVOLVING NOVEL TARGETED AGENTS? first line treatment maintenance/consolidation.

DISEASE CERVICAL CANCER WORLD HEALTH PROBLEM. ELECTRON FOTOGRAPHS OF PAPILLOMAVIRUS RESPONSIBLE FOR CERVICAL CANCER.

GBM – Oncological Management Dr H Lord Consultant Clinical Oncologist.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

GCIG Rare Tumor Working Group Chicago, IL, June 3, 2010 Chair: Isabelle Ray-Coquard Co-Chair: David M. Gershenson.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Hypofractionated vs. Standard Radiotherapy with or without Temozolomide for Older Patients with Glioblastoma Shyam K. Tanguturi MD, Ayal A. Aizer MD MHS,

Boron Neutron Capture Therapy in the treatment of brain tumours - The Swedish experience - L. Pellettieri Md. Ph. D. Professor emeritus Gothenburg University.

Making it happen: Consultant Radiographers - the vision and the reality. Kate Burton AHP Consultant Radiographer in Neuro-Oncology.

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Use of Bevacizumab in anticoagulated recurrent glioblastoma multiforme patients: An Australian experience Adrian Lee 1,2,3,4, Marina Kastelan 4,5, Helen.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Chemotherapy in Neuro-oncology Rationale Barriers to effective use of chemotherapy Chemotherapeutic agents Chemotherapy for high grade gliomas Chemotherapy.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.

ASNR 54rd Annual Meeting ASNR 54rd Annual Meeting

Business Update Conference Call

Advances in Personalized Medicine in Oncology: A Refresher for the Practicing Radiation Therapist Sophia Lamey

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Dunleavy K et al. Proc ASH 2015;Abstract 472.

The Immune System. The Immune System Adaptive Immune Response.

Improving Survival in Glioblastoma Multiforme

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Rossi A et al. Proc ASCO 2011;Abstract 8008.

Stupp Trial: Improved survival with TMZ Chemotherapy

Figure 3 Intracranial targeting of high-grade gliomas

Management of Glioblastoma

Krop I et al. SABCS 2009;Abstract 5090.

Bergh J et al. SABCS 2009;Abstract 23.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Figure 3 Overall survival, according to treatment group

Endothelial Ang‐2 upregulation correlates with WHO grading in human gliomas Endothelial Ang‐2 upregulation correlates with WHO grading in human gliomas.

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Presentation transcript:

 2009 iMedia neuroScoop.net / anocef.org Chimiothérapie Khê Hoang-Xuan Paris

 2009 iMedia neuroScoop.net / anocef.org Bevacizumab (Avastin R ) Phase II study of Bevacizumab plus etoposide among recurrent malignant glioma patients Reardon DA et al (Duke, Durham) O128 = Beva + CPT11 Phase II study: Bevacizumab plus erlotinib in recurrent high grade glioma S. Sathornsumetee et al (Duke, Durham) O130 < Beva + CPT11 Phase II study Bevacizumab plus nitrosourea (fotemustine) in recurrent malignant gliomas Ruda R et al (Turin, Italie) O129 < ou = Beva + CPT11

 2009 iMedia neuroScoop.net / anocef.org Temozolomide (Témodal R ) Récidives A continuous schedule of TMZ for GBM at first relapse may overcome the therapeutic disadvantage of non methylated MGMT: results from the phase II Rescue trial Perry J et al (Canada) O128 Dose dense one week on/one week off temozolomide in recurrent glioma Taal W et al (Rotterdam) Traitement initial Phase II trial of Talamptel with standard radiation and TMZ in patients with newly diagnosed GBM : report of two year survival data Grossman SA et al (NABTT CNS consortium, Baltimore)

 2009 iMedia neuroScoop.net / anocef.org Cediranib (Recentin R ) A Phase I open label multicenter study to assess cediranib (Recentin TM) in combination with lomustine for patients with recurrent glioblastoma Batchelor T. et al (Boston) O126 Phase III en cours Cediranib versus lomustine versus Cediranib +lomustine A Phase IB trial of Cediranib in addition to standard TMZ plus radiation therapy in patients with newly diagnosed GBM. Chi AS (Boston)

 2009 iMedia neuroScoop.net / anocef.org EFFECTS OF PREGNANCY ON NATURAL HISTORY OF WHO GRADE II GLIOMAS: A quantitative analysis of the tumor growth rates L. Taillandier and The french ANOCEF group retrospective study N=14 / 26 Mean tumoral diameter over time Before Pregnancy: 3.4mm/year During Pregnancy: 5.8 mm/year P=0.0004Kinetic increase in 10 cases (8 G II, 2 G III) increase in 10 cases (8 G II, 2 G III)  75% stable in 4 cases (4 WHO grade II ) stable in 4 cases (4 WHO grade II )  25%  25% Négative impact on tumor growth in75% of cases